Approval · Notice of Compliance 19053 · 2017
BOOSTRIX: Notice of Compliance 19053
Issued March 14, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19053
- Date
- March 14, 2017
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BOOSTRIX | Not yet assigned | — |
Medicinal ingredients
- DIPHTHERIA AND TETANUS TOXOID ADSORBED 2 UNIT per 0.5ML
- TETANUS TOXOID ADSORBED 20 UNIT per 0.5ML
- FILAMENTOUS HAEMAGGLUTININ ADSORBED 8 MCG per 0.5ML
- PERTACTIN ADSORBED 2.5 MCG per 0.5ML
- PERTUSSIS TOXOID ADSORBED 8 MCG per 0.5ML